Insights

Gathering insights about CASI…

Similar companies to CASI

G's Group
$500M$1B

CASI Tech Stack

CASI uses 8 technology products and services including RequireJS, jQuery, UPS, and more. Explore CASI's tech stack below.

RequireJS
Javascript Frameworks
jQuery
Javascript Libraries
UPS
Logistics
WP Engine
Platform As A Service
Yoast SEO
Search Engines
Bootstrap
UI Frameworks
Yii
Web Frameworks
MonsterInsights
Web Platform Extensions

Media & News

CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced the Nasdaq Hearings Panel (the "Panel") has granted CASI's request to continued listing on the Nasdaq Stock Market (the "Nasdaq") subject to the Company regaining compliance with the Market Value of Listed Securities (MVLS) Rule 5550(b)(2) by February 17, 2026. The Panel granted the extension after reviewing the recent efforts made by the Company, including the appointments of an experienced Chief Executive Officer and a new Non-Executive Chairman, a commitment to focus on execution of CID-103 development, execution of a convertible note purchase agreement, additional financing initiatives underway, and planned divestiture of China assets.
Dec 23, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI, the "Company"), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced that the Company has entered into a convertible note purchase agreement (the "Purchase Agreement") with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He (the "Purchaser"), pursuant to which the Company will issue and sell convertible notes in an aggregate principal amount of US $20 million to the Purchaser through a private placement. This investment is planned to provide runway to fund the Company through a Phase 1 study in China in renal allograft anti-body-mediated rejection (AMR) as well as development toward a stable, high concentration protein solution for subcutaneous formulation.
Dec 11, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced data presented from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP) at the 67th American Society of Hematology Annual Meeting and Exposition on December 7, 2025, in Orlando, Florida. This open-label Phase 1 dose escalation study assigned patients to sequential dose-escalating cohorts of intravenous infusions of CID-103 at 30 mg (n=1), 150 mg (n=1), 300 mg (n=3), 600 mg (n=3), and 900 mg (n=3), with a priming dose of CID-103 of either 30 mg or 150 mg administered prior to the cohort dose.
Dec 08, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Announces Changes in Board Governance
James Huang appointed as Non-Executive Chairman of CASI Board of Directors SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 19, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that its Board of Directors unanimously voted to appoint James Huang, a current independent board member, as Non-Executive Chairman of the Board, effective November 17, 2025. As part of this transition, Dr. Wei-Wu He will step down from the role as Executive Chairman and will remain a member of the Board of Directors.
Nov 19, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on the development of CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended September 30, 2025 (the "third quarter"). "We are focused on capitalizing and advancing our CID-103 clinical program in renal allograft antibody mediated rejection (AMR), first in the U.S. under an already approved IND, followed by China where a regulatory package has been accepted and is under review," said David Cory, CEO of CASI.
Nov 14, 2025 | www.accessnewswire.com
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a letter dated November 5, 2025, with a delisting determination from Nasdaq Stock Market LLC (the "Determination"). As previously reported, on May 5, 2025, Nasdaq notified the Company that its market value of listed securities (MVLS) had fallen below the minimum requirement of $35 million for 30 consecutive trading days, and as a result, did not comply with Listing Rule 5550(b)(2).
Nov 10, 2025 | www.accessnewswire.com
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that the CASI management team will participate at the Guggenheim Healthcare Innovation Conference 2025 in a fireside chat at 9:30 AM ET on November 12 in Boston, MA. CASI will also host one-on-one meetings with investors at the conference.
Nov 04, 2025 | www.accessnewswire.com

CASI's Email Address Formats

CASI uses at least 1 format(s):

CASI Email Formats	Example	Percentage
FLast@casiusa.com	JDoe@casiusa.com	97%
FirstLast@casiusa.com	JohnDoe@casiusa.com	1%
First.Middle@casiusa.com	John.Michael@casiusa.com	1%
First.Last@casiusa.com	John.Doe@casiusa.com	1%

Frequently Asked Questions

What is CASI's phone number?

You can contact CASI's main corporate office by phone at

+1-214-722-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CASI's stock symbol?

CASI is a publicly traded company; the company's stock symbol is CASI.

What is CASI's official website and social media links?

CASI's official website is casiusa.com and has social profiles on LinkedIn.

How much revenue does CASI generate?

As of December 2025, CASI's annual revenue is estimated to be $18M.

What is CASI's NAICS code?

CASI's NAICS code is 48-49 - Transportation and Warehousing.

How many employees does CASI have currently?

As of December 2025, CASI has approximately 284 employees across 5 continents, including North AmericaEuropeAfrica. Key team members include Chief Executive Officer: G. J.Chief Executive Officer: T. K.Vp Engineering: R. S.. Explore CASI's employee directory with LeadIQ.

What industry does CASI belong to?

CASI operates in the Transportation, Logistics, Supply Chain and Storage industry.

What technology does CASI use?

CASI's tech stack includes RequireJSjQueryUPSWP EngineYoast SEOBootstrapYiiMonsterInsights.

What is CASI's email format?

CASI's email format typically follows the pattern of FLast@casiusa.com. Find more CASI email formats with LeadIQ.

When was CASI founded?

CASI was founded in 2002.

CASI

Q: What is CASI's official website and social media links?

CASI's official website is casiusa.com. CASI has social profiles on LinkedIn.

Q: How many employees does CASI have currently?

CASI has approximately 284 employees.

Q: What technology does CASI use?

CASI's tech stack includes core-js, jQuery Migrate, Swiper, Twenty Twenty-One, Swoogo.

Transportation, Logistics, Supply Chain and StorageTexas, United States201-500 Employees

Cornerstone Automation Systems, LLC, better known in the industry as CASI, designs, manufactures, installs and services state-of-the-art turnkey automation solutions for pharmacy and warehouse fulfillment. We dive deep into our customers’ fulfillment processes and data to develop intelligent automated solutions that optimize our customers’ business flow.

We understand that every business is unique, so instead of trying to sell you a one-size-fits-all solution, we design each of our systems to be flexible, scalable and modular. Our goal is to provide the right balance of high-tech automation and necessary human operations - to maximize efficiency, accuracy, and profitability for each of our customers.